Neutrophilic Cholangitis

Neutrophilic cholangitis is a form of inflammatory liver disease in cats, characterized by the infiltration of neutrophils into the portal tracts and bile ducts, often associated with bacterial infection. It is part of the feline cholangitis complex, which also includes lymphocytic cholangitis and chronic cholangiohepatitis. The condition is typically classified as acute or chronic based on histopathological findings and clinical progression. Acute neutrophilic cholangitis is often associated with bacterial infection, frequently ascending from the gastrointestinal tract, while chronic cases may have a mixed inflammatory infiltrate and fibrosis. The disease primarily affects the biliary system, leading to impaired bile flow, cholestasis, and potential progression to hepatic fibrosis and cirrhosis if untreated.

The primary etiology of neutrophilic cholangitis is bacterial infection, most commonly with enteric organisms such as Escherichia coli, Enterococcus spp., Clostridium spp., and occasionally Bacteroides spp. The infection is believed to ascend from the duodenum through the common bile duct into the biliary tree, facilitated by the anatomical proximity and potential reflux of intestinal contents. Other potential causes include parasitic infections (e.g., Eurytrema procyonis in some regions), although these are less common. In some cases, no infectious agent is identified, suggesting a possible immune-mediated component or secondary bacterial translocation. Viral etiologies have been proposed but are not definitively established. Toxins and drugs that cause cholestasis may predispose to secondary bacterial infection. The exact molecular triggers involve bacterial adhesion to biliary epithelium, activation of Toll-like receptors, and subsequent recruitment of neutrophils to the portal tracts.

Neutrophilic cholangitis is primarily a disease of cats, with a higher prevalence in middle-aged to older cats (median age around 7-10 years). No specific breed predisposition has been consistently identified, although some studies suggest a higher incidence in domestic shorthair cats. There is no clear sex predilection. The condition is often associated with concurrent diseases such as inflammatory bowel disease (IBD), pancreatitis, and diabetes mellitus, collectively referred to as the 'triaditis' complex. Geographic variation may exist, with higher reporting in certain regions, but this may reflect diagnostic practices. The incidence is not well-defined, but it is considered a common hepatobiliary disease in cats, accounting for a significant proportion of feline liver disease cases.

The pathophysiology of neutrophilic cholangitis begins with bacterial colonization of the biliary tract, often due to reflux of intestinal bacteria into the common bile duct. The bacteria adhere to the biliary epithelium, triggering an innate immune response. Neutrophils are recruited to the portal tracts and bile ducts via chemokines such as IL-8 and complement components. The resulting inflammation causes damage to the biliary epithelium, leading to cholestasis, impaired bile acid transport, and leakage of bile components into the hepatic parenchyma. This can cause secondary hepatocellular injury, portal inflammation, and fibrosis. In chronic cases, the inflammatory infiltrate may become mixed, with lymphocytes and plasma cells predominating, leading to progressive fibrosis and cirrhosis. The systemic inflammatory response can result in fever, anorexia, and lethargy. If the infection ascends further, it can cause cholangiohepatitis and even hepatic abscessation. The release of pro-inflammatory cytokines (TNF-α, IL-1, IL-6) contributes to systemic signs and can lead to sepsis in severe cases.

Predisposing factors include conditions that promote bacterial translocation from the gut, such as inflammatory bowel disease (IBD), gastrointestinal neoplasia, or altered gut motility. Concurrent pancreatitis is a significant risk factor, as it can cause inflammation and obstruction of the common bile duct, facilitating bacterial ascent. Immunosuppression, whether due to concurrent disease (e.g., feline leukemia virus, feline immunodeficiency virus) or drug therapy (e.g., corticosteroids), increases susceptibility to infection. Anatomical abnormalities such as biliary strictures or gallstones can predispose to bile stasis and bacterial overgrowth. Age is a factor, with older cats being more commonly affected. Dietary factors and stress may also play a role, though evidence is limited.

Clinical signs of neutrophilic cholangitis can be acute or chronic. Acute cases often present with a sudden onset of lethargy, anorexia, vomiting, and fever. Abdominal pain may be evident on palpation, particularly in the right cranial quadrant. Icterus (jaundice) is a common finding, affecting the mucous membranes and skin. In chronic cases, signs may be more insidious, with weight loss, intermittent vomiting, and poor appetite. Some cats may show polyuria and polydipsia if concurrent renal disease or diabetes is present. Physical examination may reveal hepatomegaly, dehydration, and signs of systemic illness. In severe cases, signs of sepsis, such as tachycardia, tachypnea, and hypotension, may be present. Neurological signs are rare but can occur if hepatic encephalopathy develops secondary to severe hepatic dysfunction.

Differential diagnoses for neutrophilic cholangitis include: 1) Lymphocytic cholangitis (chronic, often with less acute signs, lymphocytic infiltration on biopsy, and less association with bacterial infection). 2) Hepatic lipidosis (typically in obese cats with prolonged anorexia, marked hyperbilirubinemia, and characteristic vacuolar hepatopathy on histology). 3) Cholangiohepatitis (inflammation of both bile ducts and hepatic parenchyma, often a progression of cholangitis). 4) Extrahepatic biliary obstruction (e.g., due to pancreatitis, neoplasia, or gallstones; imaging shows dilated bile ducts and often a visible obstruction). 5) Feline infectious peritonitis (FIP) (pyogranulomatous inflammation, positive FIP virus testing, and characteristic histopathology). 6) Toxoplasmosis (systemic signs, elevated Toxoplasma titers, and organisms on histology). 7) Hepatic neoplasia (e.g., lymphoma, adenocarcinoma; imaging and cytology/histology differentiate). 8) Cholecystitis (inflammation of the gallbladder, often with similar clinical signs but distinct imaging findings). 9) Pancreatitis (can cause secondary biliary obstruction and inflammation; serum feline pancreatic lipase immunoreactivity (fPLI) is elevated). 10) Drug-induced hepatopathy (history of drug exposure, resolution upon withdrawal).

The diagnostic algorithm for neutrophilic cholangitis begins with a thorough history and physical examination, with particular attention to signs of hepatobiliary disease. Initial laboratory tests include a complete blood count (CBC), serum biochemistry profile, and urinalysis. If cholestasis is suspected (elevated bilirubin, ALP, GGT), abdominal ultrasound is performed to assess the liver, gallbladder, and biliary tree. Ultrasound-guided fine-needle aspiration of the gallbladder or liver may be performed for cytology and culture. If cytology is inconclusive or if chronic disease is suspected, a liver biopsy (via ultrasound-guided needle biopsy or surgical wedge biopsy) is recommended for histopathology and culture. Additional tests may include serum bile acids (fasting and postprandial) to assess hepatic function, and specific tests for concurrent diseases such as feline pancreatic lipase immunoreactivity (fPLI) for pancreatitis, and feline trypsin-like immunoreactivity (fTLI) for exocrine pancreatic insufficiency. In cases where extrahepatic obstruction is suspected, advanced imaging such as CT or ERCP (endoscopic retrograde cholangiopancreatography) may be considered, though ERCP is rarely performed in cats. The definitive diagnosis is based on histopathology showing neutrophilic infiltration of the portal tracts and bile ducts, often with evidence of bacteria.

Laboratory findings in neutrophilic cholangitis typically include: Hematology: Neutrophilic leukocytosis with a left shift may be present in acute cases; toxic neutrophils may be seen. Chronic cases may have mild anemia. Serum Biochemistry: Elevated liver enzymes, particularly alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT), reflecting cholestasis. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) may be elevated due to hepatocellular injury. Hyperbilirubinemia is common, with conjugated bilirubin predominating. Total bile acids are elevated, especially postprandially. Hypoalbuminemia may occur in chronic cases. Electrolyte disturbances, such as hypokalemia, may be present due to vomiting and anorexia. Urinalysis: Bilirubinuria is common; urine specific gravity may be low if concurrent renal disease. Blood Gas Analysis: Metabolic acidosis may occur due to sepsis or concurrent disease. Specific Biomarkers: Serum feline pancreatic lipase immunoreactivity (fPLI) may be elevated if concurrent pancreatitis. C-reactive protein (CRP) may be increased as an inflammatory marker. Serology/PCR: Testing for infectious agents such as Toxoplasma, FIV, FeLV, and coronavirus may be performed to rule out other causes. Bile culture is essential for identifying the causative bacteria and guiding antimicrobial therapy.

Imaging findings in neutrophilic cholangitis include: Radiography: Abdominal radiographs may show hepatomegaly, but are often unremarkable. Ultrasonography: The liver may appear diffusely hyperechoic or have a mixed echotexture. The gallbladder may be distended, with thickened walls, and the bile ducts may be dilated. In cases of extrahepatic obstruction, a distended common bile duct may be visible. Doppler ultrasound can assess blood flow. Computed Tomography (CT): CT provides more detailed assessment of the liver and biliary tree, and can detect masses or obstructions. Magnetic Resonance Imaging (MRI): MRI is useful for evaluating the biliary system, especially with MRCP (magnetic resonance cholangiopancreatography), but is rarely used in veterinary practice. Endoscopy: Endoscopic retrograde cholangiopancreatography (ERCP) is technically challenging in cats but can be used for sampling and stenting in specialized centers. Fluoroscopy: May be used during contrast studies of the biliary tract.

Cytology: Fine-needle aspiration of the liver or gallbladder may reveal neutrophils, macrophages, and possibly bacteria. Bile cytology can show neutrophils and bacteria, but the absence of bacteria does not rule out infection. Histopathology: Liver biopsy is the gold standard. Acute neutrophilic cholangitis shows neutrophilic infiltration of the portal tracts and bile ducts, with possible bile duct hyperplasia and cholestasis. Chronic cases may have a mixed infiltrate with lymphocytes and plasma cells, fibrosis, and biliary hyperplasia. Special stains such as Gram stain can help identify bacteria. Culture of bile or liver tissue is recommended to confirm bacterial infection and guide antimicrobial therapy.

Treatment of neutrophilic cholangitis involves a multi-modal approach: 1) Antimicrobial therapy: Based on culture and sensitivity, but empirical therapy with amoxicillin-clavulanate (12.5-25 mg/kg PO q8-12h) or a fluoroquinolone (e.g., enrofloxacin 5 mg/kg PO/IV q24h) is often initiated. Metronidazole (10 mg/kg PO q12h) may be added for anaerobic coverage. Duration is typically 4-6 weeks. 2) Fluid therapy: Intravenous crystalloids (e.g., lactated Ringer's solution) to correct dehydration and electrolyte imbalances. 3) Nutritional support: Appetite stimulants (e.g., mirtazapine 1.88 mg/cat PO q48h) or feeding tubes (esophagostomy or gastrostomy) if anorexic. 4) Antiemetics: Maropitant (1 mg/kg IV/SC q24h) or ondansetron (0.5-1 mg/kg IV q12h) for vomiting. 5) Hepatoprotectants: S-adenosylmethionine (SAMe) (20 mg/kg PO q24h) and ursodeoxycholic acid (10-15 mg/kg PO q24h) to support bile flow and reduce inflammation. 6) Analgesia: Buprenorphine (0.01-0.02 mg/kg IV/SC q8-12h) for abdominal pain. 7) Surgery: In cases of extrahepatic obstruction or gallbladder mucocele, cholecystectomy or biliary diversion may be necessary. 8) Management of concurrent diseases: Treat pancreatitis, IBD, or diabetes as indicated.

The prognosis for neutrophilic cholangitis is generally good if diagnosed early and treated aggressively. Acute cases with appropriate antimicrobial therapy often resolve within 1-2 weeks. Chronic cases may require long-term management and have a more guarded prognosis, especially if fibrosis or cirrhosis has developed. Negative prognostic indicators include the presence of sepsis, severe hepatic dysfunction, concurrent pancreatitis, and lack of response to therapy. Mortality rates are not well-defined but are higher in cases with complications such as hepatic encephalopathy or disseminated intravascular coagulation. Recurrence is possible, especially if underlying predisposing factors are not addressed.

Follow-up care for neutrophilic cholangitis includes: Recheck examinations at 1, 2, and 4 weeks after initiation of treatment, then monthly until resolution. Serial serum biochemistry profiles to monitor liver enzymes and bilirubin. Repeat abdominal ultrasound at 4-6 weeks to assess resolution of biliary dilation and hepatic changes. Bile culture may be repeated if clinical signs recur. Long-term management may include continued hepatoprotectants and dietary modifications (e.g., highly digestible, low-fat diet). Monitor for recurrence of clinical signs and adjust therapy accordingly.

Pearls: 1) Always consider concurrent pancreatitis and IBD in cats with cholangitis (triaditis). 2) Obtain bile for culture before starting antibiotics to guide therapy. 3) Use ursodeoxycholic acid to promote bile flow and reduce inflammation. 4) Provide aggressive nutritional support to prevent hepatic lipidosis. Pitfalls: 1) Do not rely solely on cytology; histopathology is needed for definitive diagnosis. 2) Avoid corticosteroids unless immune-mediated disease is confirmed, as they can worsen infection. 3) Do not use drugs that are hepatotoxic or require hepatic metabolism without dose adjustment. 4) Failure to address extrahepatic obstruction can lead to rapid deterioration.

Antimicrobials: Amoxicillin-clavulanate (12.5-25 mg/kg PO q8-12h) for 4-6 weeks; Enrofloxacin (5 mg/kg PO/IV q24h) for Gram-negative coverage; Metronidazole (10 mg/kg PO q12h) for anaerobes. Adjust doses in hepatic impairment. Hepatoprotectants: S-adenosylmethionine (SAMe) (20 mg/kg PO q24h) on an empty stomach; Ursodeoxycholic acid (10-15 mg/kg PO q24h) with food. Antiemetics: Maropitant (1 mg/kg IV/SC q24h) or Ondansetron (0.5-1 mg/kg IV q12h). Appetite stimulants: Mirtazapine (1.88 mg/cat PO q48h) or Cyproheptadine (2 mg/cat PO q12h). Analgesics: Buprenorphine (0.01-0.02 mg/kg IV/SC q8-12h). Fluid therapy: Balanced crystalloids (e.g., Lactated Ringer's) at maintenance (60-80 ml/kg/day) plus deficits. Monitor for hypokalemia and supplement as needed. All dosages are based on Plumb's Veterinary Drug Handbook.

Key studies and guidelines: 1) The WSAVA Liver Standardization Group has published guidelines for the classification and diagnosis of feline cholangitis. 2) A study by Center et al. (2013) evaluated the clinical and pathological features of feline cholangitis and found that neutrophilic cholangitis is often associated with bacterial infection and concurrent pancreatitis. 3) A consensus statement from the ACVIM (2016) on the management of feline cholangitis recommends antimicrobial therapy based on culture, and the use of hepatoprotectants. 4) A study by Otte et al. (2017) reported that cats with neutrophilic cholangitis have a good prognosis with appropriate treatment, but recurrence is common. 5) Research by Tamborini et al. (2016) highlighted the importance of bile culture in guiding therapy. 6) A meta-analysis by Marolf et al. (2012) evaluated the diagnostic accuracy of ultrasound in feline hepatobiliary disease, concluding that ultrasound is useful but not definitive. 7) The ISCAID guidelines (2019) provide recommendations for antimicrobial use in hepatobiliary infections, emphasizing the need for culture and sensitivity testing.